Considering the multitude of effects driven by p53 activity in eye physiology, in vitro experimentation and clinical trials of these molecules could be undertaken to exploit the effects of p53 pathway activators for ocular disease treatment and develop novel targeted therapies for the management of ocular tumors. Here, TP53 is linked to eye neoplasm.